Source URL: https://medicines.health.europa.eu/veterinary/en/600000033233

RISPOVAL 2

Authorised

- Bovine parainfluenza virus 3, strain RLB103, Live
- ALUMINIUM HYDROXIDE GEL
- Bovine respiratory syncytial virus, strain 375, Live

Product identification

Medicine name:

RISPOVAL 2

Rispoval 2 / BRSV + Pi3, liofilizatas ir skiediklis injekcinei suspensijai ruošti galvijams

Active substance:

Bovine parainfluenza virus 3, strain RLB103, Live

ALUMINIUM HYDROXIDE GEL

Bovine respiratory syncytial virus, strain 375, Live

Target species:

Cattle

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Bovine parainfluenza virus 3, strain RLB103, Live 100000.00 log10 50% tissue culture infectious dose / 1.00 Dose

ALUMINIUM HYDROXIDE GEL

1.00 unit(s) / 1.00 Dose

Bovine respiratory syncytial virus, strain 375, Live 100000.00 log10 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration: Intramuscular use:

Cattle

- All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

OI02AD07

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Cardboard box with 1 vial of lyophilisate (5 doses) and 1 vial of solvent (20 ml) Cardboard box with 1 vial of lyophilisate (25 doses) and 1 vial of solvent (100 ml)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder: Zoetis Belgium
Marketing authorisation date: 25/11/2020
Manufacturing sites for batch release: Zoetis Belgium
Responsible authority: State Food And Veterinary Service
Authorisation number: LT/2/20/2630/001-002
Date of authorisation status change: 25/11/2020
Reference member state: France
Procedure number: FR/V/0420/001
Concerned member states: Belgium Croatia Czechia Estonia Germany Hungary Ireland Latvia Lithuania Luxembourg Netherlands Portugal Slovakia Slovenia Spain United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
RV2630.pdf